Trial Profile
An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2016
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary) ; Simvastatin (Primary) ; Fostamatinib
- Indications Hypercholesterolaemia; Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms Statin DDI
- Sponsors AstraZeneca
- 09 Jan 2016 Results published in the Drugs in R and D
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2012 New trial record